01—Abstract
Summary
Summary of the 10-Q filed November 6, 2024. Cited figures are marked; the original filing is the authoritative source.
Guardant Health, Inc. reported its third-quarter 2024 financial results, showcasing robust revenue growth driven by its precision oncology testing segment.
Total revenue increased by 34% year-over-year to $191.5 milliona, with precision oncology testing revenue growing by 35% to $180.6 million. This growth was fueled by both increased test volumes from clinical customers and biopharmaceutical clients, along with improved reimbursement rates, particularly for the Guardant360 LDT test. Despite strong top-line performance, the company continues to operate at a net loss, reporting a loss of $107.8 million for the quarter.
The company maintains a healthy liquidity position with approximately $1.0 billionb in cash, cash equivalents, and marketable debt securities as of September 30, 2024, providing runway for continued investment in research and development and commercial expansion. A significant development during the quarter was the achievement of performance metrics for certain performance-based restricted stock units (PSUs), leading to a cumulative charge of $23.5 million in stock-based compensation expense.
While R&D expenses saw a slight decrease year-over-year, sales and marketing expenses increased significantly due to commercial team build-out and marketing efforts for product launches, including the Shield test. The company also noted progress in its intellectual property disputes and continues to advance its product pipeline and international expansion efforts.
02—Key points
Key Highlights
- Total revenue for the third quarter of 2024 increased by 34% to $191.5 million, compared to $143.0 million in the prior year period.
- Precision oncology testing revenue rose by 35% to $180.6 million, driven by higher test volumes and improved reimbursement, notably for the Guardant360 LDT test.
- Net loss for the quarter was $107.8 million, a slight increase from $86.1 million in Q3 2023, reflecting continued investment in growth initiatives.
- The company ended the quarter with a strong liquidity position, holding $1.0 billion in cash, cash equivalents, and marketable debt securities.
- Sales and marketing expenses increased by 42% to $97.9 million, reflecting investments in commercial team expansion and marketing for product launches.
- Research and development expenses decreased by 7% to $87.3 million, primarily due to lower clinical study costs as the ECLIPSE study nears completion.
- Guardant Health is actively managing legal proceedings, including a patent infringement suit against Tempus AI, Inc. and a false advertising dispute with Natera, Inc.
03—One dollar
Follow one dollar
For each $1.00 of revenue in Q3 FY2024, Guardant Health, Inc. lost $0.56.
- Revenue$191.5M100.0%
- Cost of revenue−$74.5M38.9%
- Gross profit$117.0M61.1%
- Operating costs−$234.3M122.4%
- Operating income−$117.3M61.3%
- Interest, other & tax$9.6M5.0%
- Net income−$107.8M56.3%
04—Financials
Financial Highlights
Figures from 10-QQ3 FY2024filed November 6, 2024Financial Statements
Q3 FY2024 against Q3 FY2023
| Line item | Q3 FY2024Q3 FY2023 | Change |
|---|---|---|
| Revenue | $191.48M$143.03M | +33.9% |
| Cost of Revenue | $74.49M— | — |
| Gross Profit | $116.99M— | — |
| R&D Expenses | $87.31M$93.85M | −7.0% |
| Operating Expenses | $308.80M$256.57M | +20.4% |
| Operating Income | -$117.33M-$113.54M | −3.3% |
| Interest Expense | $645K$644K | +0.2% |
| Net Income | -$107.75M-$86.10M | −25.1% |
| EPS (Basic) | $-0.88$-0.73 | −20.5% |
| EPS (Diluted) | $-0.88$-0.73 | −20.5% |
| Shares Outstanding (Basic) | 123.05M117.74M | +4.5% |
| Shares Outstanding (Diluted) | 123.05M117.74M | +4.5% |
05—Questions
Frequently Asked Questions
What was the primary driver of Guardant Health's revenue growth in Q3 2024?
The primary driver of Guardant Health's revenue growth in Q3 2024 was the Precision Oncology Testing segment, which saw a 35% increase in revenue to $180.6 million. This growth was attributed to higher test volumes from both clinical and biopharmaceutical customers, coupled with improved reimbursement rates, particularly for the Guardant360 LDT test.
Despite revenue growth, why did the company report a net loss?
Guardant Health continues to invest heavily in research and development, sales, and marketing to drive future growth and market adoption of its products. Increased spending in sales and marketing, along with ongoing R&D investments, contributed to the net loss of $107.8 million for the quarter, despite the strong revenue performance.
What is the company's current financial health and outlook regarding liquidity?
The company maintains a strong liquidity position, with approximately $1.0 billion in cash, cash equivalents, and marketable debt securities as of September 30, 2024. Management believes this is sufficient to meet its anticipated cash requirements for more than 12 months. Guardant Health may also explore additional capital raises if needed for expansion or strategic investments.
Are there any significant legal or regulatory matters that investors should be aware of?
Guardant Health is involved in several legal proceedings, including an ongoing patent infringement suit against Tempus AI, Inc. and a false advertising dispute with Natera, Inc., with a trial scheduled for November 2024. The company is also cooperating with a Civil Investigative Demand from the U.S. Attorney concerning billing for genetic tests. While these matters carry inherent risks, the company is actively defending its position.
06—Continue